OREGON STATE UNIVERSITY



COLLEGE OF PHARMACY

ACADEMIC REPORT FOR 2005-2006

1. 2005-2006 Highlights

a. Programmatic achievements

▪ Initiatives in support of student engagement and success

After a year of extensive preparation described in last year’s report, the college was visited by an evaluation team from the Accreditation Council of Pharmacy Education (ACPE) in October of 2005. As an outcome, the professional doctor of pharmacy (Pharm. D.) program was granted continuing accreditation in January 2006. The team report was complimentary of our curriculum in general, the quality of our students, faculty collegiality, the college’s commitment to students success, and enhanced staffing in the college’s office of student affairs.

The accreditation team’s concerns focus on inadequate financial resources that result in a smaller than desired faculty size, salaries that are markedly below market value, and need for improved articulation between the Corvallis and Portland faculty and student experiences. Progress in the college’s outcomes assessment process was cited, but further information as to the overall assessment plan was requested. Several curricular questions were raised, some of which are indirectly linked to our small faculty size and articulation between campuses. An interim report will be submitted to ACPE in early 2007 and a focused on-site evaluation visit will occur in the fall of 2007.

In response to the accreditation findings, several immediate actions were taken. A financial plan to significantly raise student tuition, with all new revenues to come directly to the college, was approved by the Provost and the Vice President for Finance and ultimately approved by the OUS Board for implementation in fall 2006. Further tuition increases are proposed for autumn 2007 and 2008. In anticipation of the first phase of new revenue, several faculty recruitments have been initiated and a plan has been submitted to take the first steps toward addressing salary inequities. The following new faculty have been hired:

Chrissa Kioussi, Ph. D. Assistant Professor, Pharmacology (replacement for Tony Collins)

Joel Marrs, Pharm. D. Clinical Assistant Professor, Internal Medicine (replacement for Nanette Bultemeier)

Jessina McGregor, Ph.D. Assistant Professor, Pharmacoepidemiology (new position)

Stacy Ramirez, Pharm. D. Clinical Assistant Professor, Community Practice (new position)

Craig Williams, Pharm. D. Clinical Associate Professor, Internal Medicine (replacement for Michelle Liedtke)

Vickie Staffelbach, MPA, Director of College Administration (replacement for Evelyn Madison)

The following faculty searches are either in progress or will be initiated this summer:

Assistant Professor, Cardiology (new position)

Assistant Professor, Clinical Pharmacokinetics (1 or 2, replacements for Donna Belle and Sandra Earle)

Assistant Professor, Medicinal Chemistry (replacement for Bill Gerwick). Note: an offer has been made to Dr. Kerry McPhail, Ph.D., with an anticipated start date of Sept. 2006)

Assistant Professor, Pharmacoeconomics/ Health Systems (1 or 2, replacements for Lee Strandberg and Dan Touchette)

Clinical Assistant Professor, Community/ Ambulatory Practice (1 or 2, replacement for Diane Nauman and one new position)

The move to the new building on the emerging OHSU riverfront campus late in 2006 will provide expanded classroom space, faculty offices, research space, and a more positive atmosphere for both faculty and students in Portland. The new department chair in Portland (Dr. Matthew Ito) is nearing the end of his first year at OSU and is committed to promoting a greater sense of collegiality between the faculty and a welcoming environment for students. Starting next academic year, members of the advising staff will schedule regular hours to travel to Portland to assist students. A tentative plan is for the Director of Alumni and Student Relations to relocate to Portland in July 2007, but still come to the Corvallis campus once a week.

Tempering these positive steps are multiple faculty retirements and resignations on both campuses (see above for replacement positions) that challenge our ability to effectively teach several required course during the coming year, significantly higher salaries and startup costs for the new hires, and the additional financial liability of over $200,000 per year to pay for the higher cost of leased space in the new Portland facility.

As part of the college’s continuing commitment to academic excellence and in response to the accreditation report, the curriculum committee rigorously reviewed the first professional year curriculum during the last several months. Several course changes have been approved by the faculty to improve sequencing of student learning. Departmental retreats are scheduled for this summer to update departmental strategic plans and further review the curriculum.

As discussed in detail in last year’s report, Senior Lecturer Ann Zweber was appointed as the college’s director of assessment and chair of the assessment committee in the fall of 2004. Her committee did considerable work to conduct surveys of the students, faculty, and alumni in preparation for the accreditation site visit. The results of these surveys were used as a guide by the curriculum committee in its deliberations to modify or revise the professional program. The assessment committee continues to meet frequently to develop a more comprehensive assessment plan as recommended by the accreditation report.

The College of Pharmacy is committed to providing a welcoming atmosphere for its students and staff, promoting professionalism, and ensuring student success. Numerous events are scheduled throughout the year to bring students, faculty, and in some cases, alumni, together and to continually instill the spirit of collegiality and professionalism. Among the key events are:

A three day orientation program for incoming students before the start of fall quarter

A one day orientation program in Portland for third year professional students

The White Coat Ceremony in the fall for incoming students

An all college luau and pig roast in the in the fall

The Benefactor’s Reception in the fall for scholarship recipients to meet their donors

The Homecoming Brunch

The student recognition banquet and talent show in the spring

The College of Pharmacy graduation recognition ceremony

▪ Major research/scholarship initiatives

During the 2005-06 fiscal year, College of Pharmacy faculty received 23 grants totaling $1,468,457. As anticipated, this represents a decline from the previous fiscal year, largely a function of the move of Professor William Gerwick to the University of San Diego and secondarily a reflection of cutbacks in NIH funding at the national level. We anticipate a steady growth in research funding over the next biennium as newly hired junior faculty reach full productivity. Our goal is to reach $3 million in extramural funding within the next two biennia.

See Appendix A: Grants and Contracts Awarded (listed alphabetically by faculty PI)

See Appendix B: Publications, Presentations, Awards, Travel, Service, and Other by

Faculty (listed alphabetically by faculty last name)

Listed below is an updated summary of the research initiatives within the college of pharmacy. These initiatives remain fundamentally unchanged from last years’ report and are closely aligned with the strategic plans of the university, the college, and the two college departments. Specifically they address the OSU thematic area of realizing fundamental contributions in the life sciences and optimizing the health and well-being of the public. All new tenure track faculty hired in the last year or being recruited are targeted to participate in these research focus areas.

▪ Areas of research focus include:

o A multidisciplinary, translational infectious diseases research program has been initiated with collaborations between the Departments of Pharmaceutical Sciences and Pharmacy Practice and the Colleges of Pharmacy, Veterinary Medicine, and Science. The emphasis on the Corvallis campus is on the discovery of novel naturally occurring and semi-synthetic antibacterial molecules. Complementary investigations are examining the creation of new vaccines and novel modes of vaccine delivery. Early in 2006, Vice President for Research John Cassady convened a steering group co-chaired by Luiz Bermudez (Veterinary Medicine) and Mark Zabriskie (Pharmaceutical Sciences) to further define the mission of infectious disease research at OSU and the potential for a broader drug discovery program beyond antibiotic compounds. In turn, this group participated in development of a statewide signature research center proposal entitled The Oregon Drug Discovery & Translational Research Institute (ODDTRI). This is a joint proposal by Oregon Health & Science University (OHSU), Oregon State University (OSU), Portland State University (PSU), University of Oregon, and several Oregon-based biotechnology companies. The institute will focus on the development and commercialization of therapeutics, vaccines, and diagnostics for infectious diseases, neurodegenerative disorders, cancer and other major problems affecting human health. A primary objective of this proposal is to create a unique drug development consortium and facility that will bridge the gaps between basic research, development and commercialization. This proposal is currently under review by Oregon Innovation Council (Oregon InC), a legislatively appointed research engine for the state.

Faculty: Mark Zabriskie, Ph.D., Professor of Medicinal Chemistry; Taifo Mahmud, Ph.D., Assistant Professor of Medicinal Chemistry; Phil Proteau, Ph.D., Associate Professor of Medicinal Chemistry; J. Fred Stevens, Ph.D., Assistant Professor of Medicinal Chemistry; Patricia Flatt, Ph.D., Senior Research Assistant Professor of Medicinal Chemistry; Kerry McPhail, Ph.D., Senior Research Assistant Professor of Medicinal Chemistry; Xihou Yin, Ph.D., Senior Research Assistant Professor of Medicinal Chemistry; Zhengrong Cui, Ph.D., Assistant Professor of Pharmaceutics

o A complementary component of the translational infectious diseases research program is conducted by faculty on the Portland campus who conduct research to identify mechanisms of antibiotic resistance, test novel dosing models in humans, and perform pharmacoeconomic/cost effectiveness analysis of marketed antibiotics. Current work includes studies of bacterial resistance to fluoroquinolones, in various organisms, including Staphylococcus aureus, Pseudomonas aeruginosa, and Streptococcus pneumoniae. This research includes collaborations with Corvallis faculty and OHSU’s Molecular Medicine Institute. In addition, pharmacokinetic modeling of various antimicrobials in special populations is studied as well as assessment of pharmacists’ involvement in vaccine preventable diseases.

Faculty: George Allen, Pharm.D., Assistant Professor of Pharmacy Practice; David Bearden, Pharm.D., Assistant Professor of Pharmacy Practice; Jessina McGregor, Ph. D., Assistant Professor of Pharmacy Practice (Pharmacoepidemiology)

o A focus of the pharmacology section of the Department of Pharmaceutical Sciences is to refine and expand our understanding of cell signaling as it pertains to activation of cellular processing and control of gene expression. Development of genetically modified small rodent models that facilitate our understanding of the significance of alterations in organisms is an emphasis of these studies. Investigations include a range of therapeutic concerns from ischemic diseases, cardiovascular function and cancer. Small rodent models of disease currently available are targeted toward mechanisms involved in for melanoma, leukemia and fetal development.

Faculty: Mark Leid, Ph.D., Professor of Pharmacology; Theresa Filtz, Ph.D., Assistant Professor of Pharmacology; Jane Ishmael, Ph.D., Assistant Professor of Pharmacology; Arup Indra, Ph.D., Assistant Professor of Pharmacology; Chrissa Kioussi, Ph.D., Assistant Professor of Pharmacology.

o Cardiovascular disease pharmacotherapy. Current activity in this group includes clinical trials and pharmacokinetic, pharmacodynamics, metabolic, and pharmacoeconomic/cost effectiveness studies of new and existing lipid lowering drugs. Novel patient programs for improving patient care in patients with lipid disorders and congestive heart failure are evaluated. Collaborative efforts have been initiated with the OHSU cardiovascular division and Heart Research Center. The hiring of several new faculty who will join the group in summer and fall of 2006 will expand the research to include hypertension, heart failure and other chronic cardiovascular diseases.

Faculty: Matthew K. Ito, Pharm.D., FCCP, BCPS, Professor and Chair; Terri Bianco, Pharm.D., Associate Professor of Pharmacy Practice; Harleen Singh, Pharm.D., Assistant Professor Pharmacy Practice; Joel Marrs, Pharm. D. Clinical Assistant Professor of Pharmacy Practice; Craig Williams, Clinical Associate Professor of Pharmacy Practice; Judi Low, BSN, Research Assistant

o Pharmaceutics faculty examine metabolic processes and mechanisms of drug disposition that influence the therapeutic utility of drugs. Investigations explore genomic influences on drug metabolism and how this may alter pharmacokinetic models and drug toxicity.

Faculty: Rosita Proteau, Ph.D., Associate Professor of Pharmaceutics; J. Mark Christensen, Ph.D., Associate Professor of Pharmaceutics

o Faculty on the Portland campus are developing a pharmacokinetics/ pharmacodynamics modeling and consulting program as a component of the OHSU School of Medicine’s Pharmacokinetics Core. Areas of research are in infectious diseases, nephrology, and oncology. Progress in this research area has been slowed by the recent resignation of two faculty. New faculty searches are currently underway.

Faculty: Myrna Munar, Pharm.D., BCPS, Associate Professor of Pharmacy

o The Drug Use Research and Management (DURM) Program now employs 5 clinical pharmacists and 2 support staff in Portland and Salem. They work with the Oregon State Medical Assistance Program and Care Oregon to help shape state policies for the cost-effective use of medications for low-income families. Their research evaluates policies and methods to improve the use of prescription drugs. This program is described further on page 7 of the report as part of the “major outreach and engagement activities” section.

Faculty: Dean Haxby, Pharm.D., Associate Professor of Pharmacy Practice and Director; Dan Hartung, Pharm.D., Research Associate; Ann Hamer, Pharm.D., Clinical Pharmacy Specialist; Rose-Ellen Hope, BS, Clinical Pharmacy Specialist; Kathleen Ketchum, Pharm.D., Program Coordinator; Michele Koder, Pharm.D., Clinical Pharmacy Specialist; Naomi Pierce , Administrative Program Specialist; Luke Middleton, Programmer.

o Pharmacoeconomics and biostatistics. These faculty conduct economic evaluations of pharmaceutical and other therapies, assess practice patterns and subsequent outcomes, and use large data bases (such as medical claims data bases) to develop and test hypotheses about occurrence of disease and treatment patterns. Clinical areas include oncology (brain tumors and chemoprotective agents), cardiology, diabetes, neurology, osteoporosis, and women’s health. Progress in this research area has been slowed by the recent resignation of two faculty. New faculty searches are currently underway.

Faculty: Dale Kraemer, Ph.D., Associate Professor, Biostatistics, Pharmacoeconomics and Outcomes Research

o The EMPOWER diabetes management demonstration and research project has been launched in partnership with the directors of the human resource departments from the cities of Eugene and Springfield and Lane County. This program is designed to assess the impact of the community pharmacist’s education of patients on diabetes control and healthcare utilization. To date 20 pharmacists have been trained and 60 patients have been enrolled. Recruitment of other employers in Lane, Benton, and Linn Counties is ongoing. Further description of the EMPOWER project are found on page 8 of the report as part of the “major outreach and engagement activities” section.

Faculty: Dale Kraemer, Ph.D., Associate Professor, Biostatistics, Pharmacoeconomics and Outcomes Research; Terri Bianco, Pharm.D., Associate Professor of Pharmacy Practice; Wayne Kradjan, Pharm.D., BCPS, Dean and Professor of Pharmacy Practice; Stacy Ramirez, Pharm. D., Clinical Assistant Professor; Judi Low, BSN, Research Assistant

▪ Major outreach/engagement initiatives

Activities from the previous year’s report continue and are reproduced below with only minor modifications.

The student pharmacy association (TRIAD) conducts a variety of community outreach programs that include presentations on asthma, poison prevention, and substance abuse avoidance to elementary, middle school, and high school students; asthma, diabetes, and hypertension screening at pharmacies in the Corvallis and Portland areas; and collaborates with pharmacists across the state to provide flu shots in local pharmacies. The Phi Delta Chi fraternity partners with parish nurse organizations and OSU County Extension Agents in Corvallis, Medford, and Portland to provide brown bag medication reviews for senior citizens at local churches.

For the past ten years, the College of Pharmacy has supported the administration of the state’s Medicaid program for low-income elderly, children, and disabled residents under the provisions of a statewide interagency agreement with the Department of Human Services (DHS), Office of Medical Assistance Programs (OMAP.) The resulting Drug Use Research and Management (DURM) program has enhanced the safety, effectiveness, and cost-efficiency of prescription drug use for Medicaid patients in Oregon. A secondary contract exists with Care Oregon, a health maintenance organization that serves Medicaid patients in the greater metropolitan Portland area. Seven full-time OSU employees (five pharmacists and two support staff) comprise the DURM team, headed by Dr. Dean Haxby, associate professor of pharmacy practice. Their responsibilities include administering the Oregon Drug Use Review (DUR) Board for DHS, evaluating drug utilization patterns among Oregon Health Plan (OHP) members, analyzing and making recommendations to DHS on drug use policies, and developing education strategies for Oregon Health Plan clinicians. In May 2004, DHS and the DURM team launched two new prescriber education programs—the Polypharmacy Review Program and the Plan Drug List (PDL) Education Initiative. The OMAP contract is being re-written to transfer oversight to the Office Sponsored Programs in the Research Office and to adjust the facilities and administration charges to the off-campus rate of 26%. Gross revenues from this contact have grown steadily over the last several years and are expected to approach $900,000 annually in the 2007 fiscal year.

The college’s strategic plan states a goal to increase the visibility and service of the college to the pharmacists and citizens of the state. Accordingly, development of a center for innovative pharmacy practice and entrepreneurship is a major initiative in the college’s strategic plan and its capital campaign agenda. As an initial step, several members of the Department of Pharmacy Practice initiated a demonstration/ research project in cooperation with the human resource directors for the cities of Eugene and Springfield and Lane County. Additional employers in Benton, Lane, and Linn Counties are being recruited with plans to expand to the Portland Metropolitan area in late 2007 or early 2008. The primary goal of this research is to demonstrate the health related and economic impacts of a pharmacist-delivered patient empowerment program (education and medication therapy management) for diabetics. This project will assess the impact of waiver of co-pays for diabetes-related utilization with and without a pharmacist directed empowerment program. If this project is successful, it will be expanded to other parts of the state and provide pharmacists’ care for additional chronic health problems.

▪ National/International impact of programs and initiatives

The pharmaceutical sciences research (e.g., infectious diseases, drug discovery, and genetically modified mouser modeling), the DURM Medicaid Program, and the EMPOWER research project described above serve as examples to programs in other states and help to enhance the college’s national reputation.

In collaboration with Mark Merickel in Extended Campus, the directors of pharmacy for several large employers (Bi-Mart, Fred Meyer, Safeway, and Samaritan Health Systems), and a business consultant from Linn Benton Community College, the college developed a 9 module, 18 hour web-based continuing education course for practicing pharmacists on human resource management. Marketing for this course to Oregon employers, national pharmacy associations and all colleges of pharmacy in the US will begin in August 2006.

b. Faculty recognition and awards

Angela Austin-Haney, Director of Student Services and Head Advisor is the Chair-Elect for the Academic Advising Council for 2006-2007.

David Bearden was promoted to clinical associate professor

Gary DeLander served as President of the Rho Chi national pharmacy honorary society.

Gary DeLander was appointed to the 2006-07 Pharmacy College Application Service (PharmCAS) National Advisory Panel.

Advisor, Nicole Kent, was given a certificate of merit for Outstanding New Advisor by the National Academic Advising Association.

Matthew Ito was appointed to the Steering Committee for the Pacific Chapter of the National Lipid Association (NLA).

Deanna Moretz was elected to serve as Secretary for OSHP Board of Directors 2006-2008, continuing to co-chair Educational Affairs Committee with Rob Rosenow, Dean at Pacific University

Diane Nauman served as the pharmacist spokesperson in an educational video on head lice treatment produced by Tec Labs of Albany, Oregon. Pharmacy footage for the video was shot at a local independent pharmacy in Corvallis. The video will be distributed nationally through PTA organizations to educate parents about head lice prevention and treatment in children.

Diane Nauman was featured in the “Faces of OSU” promotional series at Oregon State University.

Diane Nauman was invited to join the Oregon Patient Safety Commission - Prescription Medication Safety Legislative Taskforce as a representative from the OSU College of Pharmacy.

Dr. Rosita Proteau served as Chair of the Education Committee and Chair of the Minority Initiatives Subcommittee of the Society of Toxicology and President of the Regional Pacific Northwest Association of Toxicologists.

c. Student recognition and awards

Three OSU students were individually recognized at the American Pharmacists Association-Academy of Students of Pharmacy (APhA-ASP) annual meeting in San Francisco in April. Mike Fahey served as the APhA-ASP Region Seven Delegate and was appointed to the APhA-ASP national Policy Committee. Mia Ha was elected as APhA-ASP Region 7 Member at Large. Linda Wylie was the Oregon State University Representative to APhA Patient Counseling Competition.

Three OSU students were individually recognized at the American Society of Health Systems (ASHP) annual Student Society meeting in Las Vegas. Sarah Hilbert was elected to the Leadership Development Subcommittee. Andrea Larkin and Wendy Kagawa formed the team representing OSU at the ASHP Clinical Skills Competition.

Martha Kuhn received the United States Public Health Service Excellence in Public Health Pharmacy Practice Award during the college’s graduation recognition ceremony in June.

Strategic Plan Implementation

a. Focus for 2005-2006: Enhancing student success, increasing research and outreach, and enhancing diversity and community

▪ For each focus area, list the initiatives undertaken and the outcome at the end of the year (include international dimensions within diversity)

▪ Provide a brief self-assessment of the unit efforts in the three areas: what worked; areas that need improvement; major barriers

Enhancing Student Success

Congruent with the university’s strategic plan, the college strives to pursue excellence in professional and graduate education by providing a faculty, curriculum, and learning environment that assures student access, retention, and success in the academic programs and throughout their professional careers. The college has an ongoing commitment to curricular review, systematic assessment, and enhancement. This commitment was underscored during the past year as we prepared for and ultimately received re-accreditation of the professional (Pharm. D.) degree program by the Accreditation Council for Pharmacy Education (ACPE). See the “initiatives in the support of teaching” section on page one in this report for an expanded description of this area.

Increasing Research and Outreach

See section on “Major research/scholarship initiatives” above (pages 3-7)

See section on “Major outreach/engagement initiatives” above (pages 7-8)

Enhancing Diversity and Community.

As described in the 2005 report, surveys were sent to faculty, staff, current students, and recent graduates as part of the accreditation self study to assess their impressions of the quality of the education provided and the success of the college in providing a nurturing environment. Several questions in each survey ask if faculty, staff, and students treat each other equally regardless of gender, age, racial, or ethnic background. The results of the surveys from faculty, staff, and recent graduates were included in the 2005 diversity report and the accreditation self study. We will continue to survey all future graduating cohorts approximately 1.5, 3, 5, and 10 years post graduation.

The college advisors and the college’s director of alumni and student relations continue to attend many health career fairs, including those aimed at students in the Portland metropolitan area from high schools that have a high enrollment of underrepresented students. We also partner with OHSU as part of their Comprehensive Health Careers Opportunity Program (HCOP) grant which focuses on attracting disadvantaged students and minorities to careers in the health sciences. Because admission to the college requires a minimum of three years of prior college level coursework, recruitment aimed at high school students has a relatively low yield. For the last two years college advisors have visited the OSU cultural centers as an outreach to students already on campus. The new director of alumni and student relations has extensive background with the OSU Student Ambassadors program for the Colleges of Agriculture and Forestry and brings specific knowledge of recruitment strategies for Native American students to the college.

The College of Pharmacy faculty currently meets, but does not exceed, the diversity of applicant pools of qualified prospective faculty members. We have been successful in recruiting women and Asian faculty (three of five new faculty hired this year are female) and have two faculty of Hispanic descent. We continue to be unsuccessful in recruiting Black and Native American faculty. This is partly a factor of a small nationwide pool of underrepresented minorities in pharmaceutical sciences graduate training programs and an inability to compete with the monetary rewards of pharmacy practice positions in the community setting for Pharm. D. trained students of all backgrounds.

A new college diversity committee was formed in September 2006, chaired by Dr. Rosita Proteau. The charge of this committee is to:

Develop a college-specific definition of diversity and corresponding diversity mission, vision, and value statements. Help keep faculty, staff, and students aware of programs developed by the university’s Office of Community and Diversity. Attend to the university’s goals to: (1) attract diverse people including faculty, staff, and students; (2) ensure a welcoming and inclusive atmosphere; (3) assure that faculty, staff, and students demonstrate cultural sensitivity, including inclusion of these topics in curricular offerings; and (4) create an atmosphere where all can have a comfortable conversation about sensitive topics.

Each year, the committee will determine which issues they most want to emphasize (e.g., student and faculty recruitment and retention; diversity and cultural competency of the curriculum; faculty, staff, and student diversity and cultural competency discussions; and/or diversity climate initiatives). This committee will also work with the Outcomes Assessment Committee to coordinate periodic cultural competency assessment of the faculty, staff, and students.

A minimum of three faculty, two staff, and two students comprise the membership of this committee. Both academic departments and both campuses (Corvallis and Portland) are represented. Membership of courtesy and/or affiliate faculty is also encouraged.

Since January, the College of Pharmacy Diversity Committee met several times via face to face meetings (using the college’s video conferencing network) and emails. Dr. Terryl Ross met with the committee to discuss how he would like the college to develop its Diversity Action Plan (DAP). Appendix C of this report is the current working draft of the college’s DAP which is still undergoing revision. It will be sent to the college’s constituency (administration, faculty, staff, and students) for their input later this summer or at the beginning of fall quarter. Based upon the feedback received, the final DAP report will be submitted to Dr. Ross in the fall.

Within the current draft, five planning priorities have been identified with an estimated timeline and measurable objectives. These priorities are listed on page 19 of this report in the section entitled “Proposed Priorities for 2006-2007. Because the college of pharmacy does not have numerical values to truly assess retention of underrepresented and marginalized communities within the college, the first priority focuses on assessing the retention of the students, faculty and staff. The next three priorities focus on activities within the College, while the last one focuses on external factors.

b. Summarize major unit activities during 2005-2006 that helped promote one or more of the five thematic areas

Oregon State University’s Strategic Plan for the 21st Century indicates an aspiration to become a top 10 land grant institution. Among the five thematic focus areas of the university is to “realize fundamental contributions in the life sciences and optimizing the health and well being of the public.” As the strategic plan further states, “around these existing strengths, we will build an integrated and novel program focused on the prevention of disease, biomedical discovery and application, and the promotion of health.” An emerging area of specific strength poised for substantial growth within the health and life sciences theme relates to infectious disease research and drug discovery. The College of Pharmacy plays a leading role in advancing this theme as described in the section of this report entitled “major research and scholarship initiatives” (pages 3-6). The College of Pharmacy is committed to expanding its research programs in bioorganic chemistry and natural products (antibiotics) drug discovery as part of the statewide signature research initiative in Drug Discovery and Translational Research.

c. Summarize major accomplishments for 2005-2006 in support of the OSU Capital Campaign

The college of Pharmacy has three major initiatives for the capital campaign that parallel the university’s strategic plan and the mission of the college.

• Scholarships. Enhancing student engagement and success requires making the educational experience affordable and accessible. Endowed and current use scholarships, and other funds for student enrichment through the Dean’s Fund for Excellence contribute to goal to recruit Oregon’s best and brightest. Student support allows them to focus on their studies and maximize their educational pursuits. In addition to increasing annual fund contributions to scholarships, our goal is to obtain $1 million in new scholarship endowments over the course of the capital campaign. During the past year, three alumni established new named scholarships in amounts ranging from $25, 000 to $30,000. Another individual pledged $100,000 for scholarships, though the terms of the pledge have not been finalized.

a. Drug Discovery. The drug discovery and infectious diseases research initiatives of the college are described throughout this report. Current antibiotics are rapidly becoming ineffective in the face of new diseases and resistant microorganisms. At the same time, major drug companies are putting few resources toward developing new antibiotics. To fill the gap, pharmacy researchers are working to find compounds that hold promise as new antibiotics. An endowment of $1 million will help retain and attract faculty to accelerate this mission. Current-use funds will purchase equipment and other supplies.   A pledge of $100,000 in support of this initiative is being pursued with an alumnus who is a member of the OSU Foundation Board.

• Progressive Pharmacy Practice and Entrepreneurship. Prescription drug therapies are a key ingredient to preventing emergence of life threatening diseases and improving the quality of life and productivity of patients with chronic illnesses. These life saving interventions are of little value if patients are not able to afford needed medications or if they do not take them correctly. Research has shown it is cost-effective and practical for a pharmacist to be the primary patient care specialist for certain disease states. The EMPOWER project in Lane County and the DURM Program described earlier in this report (see pages 6 and 7) are the first steps of the college in developing innovative practice models and entrepreneurship. As part of the capital campaign agenda for the college, we propose to raise $1.5 million to establish an endowed program or professorship for innovative pharmacy practice that will serve the needs of the pharmacists of the state and improve the health of the citizens.

3. Other initiatives and their outcomes [e.g., Faculty/Staff Professional Development Activities]

Primarily through the use of Foundation Funds, the college pays meeting registration and travel expenses for junior faculty to attend professional meetings, especially if they are presenting a paper or serving on a committee or task force. In particular, all faculty are encouraged to attend the annual meeting of the American Association of Colleges of Pharmacy. This organization offers programming aimed for new faculty orientation, improving teaching, and leadership training.

As part of their start up package, new faculty are given funding to participate in the year long grant writing workshop coordinated by the College of Health and Human Sciences.

Our past Director of College Administration, Evelyn Madison, wrote a proposal to the Pharmacy Advisory Council requesting funds for Classified Staff Professional Development. The proposal was approved and awarded $2500. To date the staff have taken on-line web design courses, attended a technology security conference, a seminar on designing publications, a communications seminar, and computer software courses. They have purchased software from an audio conference on grammar, style and usage, and purchased subscriptions to professional training magazines. The staff continue to take professional development courses and seminars offered by Oregon State University’s Professional Development program.

4. Scorecard

a. Performance on college-level metrics

The information in the tables on the next two pages was partially provided by the office of institutional research, with other sections generated by the college of pharmacy.

| |

|College of Pharmacy |

| |

| | | | | | | |

|  |  |  |  |  |

| | |2002-03 |2003-04 |2004-05 |2005-06 |2007-08 |

| | | | | | | |

|  |  |  |  |  |  |  |

|1.4 |% of U.S. Minority Students of Total College Enrollment |37 |34.4 |32.3 |31.8 |33  |

|2.2 |6-Year Graduation Rate (% Within College / % Within University) |N/A |N/A |N/A |N/A |N/A |

|2.3 |First Professional (PharmD) Degrees Awarded |55 |70 |64 |76 |80  |

|2.6 |Student Primary Major to Faculty FTE Ratio / Student Course to Faculty FTE Ratio |28.6 / 18.9 |30.3 / 19.1 |14.5 / 14.4 |TBA |  |

|3.2 |Private Giving Revenue |$315,670 |$215,145 |$302,565 |$483,626 |- |

| |"NA" -- Not Applicable: "TBA" -- Awaiting data requested from OSU unit. |

Admission and Graduation Statistics

|Entering Class year |Size of Class |Graduate in four years |Total Graduates |

|Fall 1999 |69 |June 2003: 56 (81%) |63 (91%) |

|Fall 2000 |78 |June 2004: 66 (85%) |76 (97%) |

|Fall 2001 |72 |June 2005: 57 (79%) |68 (94%) |

|Fall 2002 |79 |June 2006: 66 (84%) |70 (89% |

|Fall 2003 |83 |June 2007: 75 (90%) (estimated) |80 (96%) (estimated) |

|Fall 2004 |83 |June 2008 | |

|Fall 2005 |85 |June 2009 | |

b. Leveraging resources

▪ Initiatives to leverage state resources

Pharm. D. tuition was raised by $2, 500 per year for incoming Pharm. D. students with a plan to further increase tuition by $1,000 per year for the next two academic years. Revenues from the differential tuition will be returned directly to the college to hire new faculty, address faculty salary inequities, enhance the student learning experience, and pay for increased expenses associated with moving to the new building in Portland.

▪ Initiatives to improve administrative efficiencies

None to report

5. Assessment of your 2005-2006 Priorities

Provide a Brief assessment of your 2005-2006 priorities, including a self-assessment of what worked, what did not, and lessons learned.

Activities during the past academic year mirrored the priorities articulated in report entitled the “Top Four Initiatives for AY 2005-06” submitted in September of 2005. A copy of that document can be provided upon request. Briefly those initiatives (and their sub-initiatives) included:

Achieving continued accreditation of the professional doctor of pharmacy program

Continuing curricular review in response to the college assessment activities

Recruiting and hiring faculty to meet curricular needs and emerging research priorities

Continuing support and growth of the research agenda around drug discovery, infectious diseases, developing and refining models of disease and drug action using models of genetically modified mice, cardiovascular diseases, and clinical pharmacokinetics.

Continuing to serve the Oregon Medical Assistance Program (OMAP) and Care Oregon through the college’s Drug Use Research and Management (DURM) program.

Implementing the EMPOWER Project.

Developing a business plan for the College of Pharmacy to support new faculty and improve faculty salaries

Actuating the college Diversity Plan Committee

Continuing development and implementation of the university campaign priority goals for the college of pharmacy

As described in the body of this report, the college successfully addressed either completely or partially all of the initiatives. The greatest accomplishments are achieving continued re-accreditation of the professional program, gaining approval of a business plan to increase tuition revenue to the college, developing a process to begin addressing salary inequities, hiring of several new faculty, inclusion of the infectious disease research program in the Oregon Drug Discovery and Translational Research Institute signature research proposal, starting the EMPOWER project, and actuating the Diversity Plan Committee.

Turnover of faculty has partially offset the gains achieved by the hiring of new faculty. Research funding declined temporarily; there are delays in our cardiovascular, pharmacoeconomics, and clinical pharmacokinetics research agendas; and we continue to be challenged with identifying faculty to teach some of the Corvallis based courses. We anticipate that each of these areas will improve during the 2006-07 academic year.

“Lessons learned” include the following:

1. We need to pay more attention to the process of transition from Corvallis to Portland/OHSU to minimize student discomfort.  As a result, the new Department Chair in Portland is focused on the transition issue and student advisors are increasing the amount of time that they spend on the Portland campus.

2. Continuing political realities at the state level require the need to continually develop revenue streams that are independent of the state general education budget. Substantial increases in professional student tuition are already being used as a mechanism to achieve greater independence from state sources, but this has limitations that could result in decreased overall recruitment. Of particular concern is the effect on populations with restricted personal finances and a negative impact on diversity goals.  Increased funding in the form of grants and contracts, though extremely important for the scholarly production of the college, are not readily available to support the professional education and is also subject to limitations because of shrinking federal budget allocations for science and health research.  Other means being pursued by the college to leverage state funding include joint faculty appointments with pharmacy employers, a potential faculty hire to develop a revenue-generating clinical pharmacokinetic/drug analysis service, and increased donor support through the capital campaign.

3. The opening this fall of a new private school of pharmacy in Portland requires a re-examination and re-configuration of our marketing plan which is currently underway.  In the near future, close attention will be paid to application numbers and acceptance rates of admitted students to assess and adjust for the potential impact of a second choice for students in pharmacy schools in the state.  

4. Changes at the National Institutes of Health in funding priorities and decreases in overall real dollar funding levels required a re-examination of our R01 research programs and strategies for retaining funding.   As a result, hiring in both departments has become more focused on building collaborative groups around common research themes (e.g. the anti-infectives medicinal chemistry initiative and the mutant mouse models of disease initiative in pharmacology).  We will also see an increased reliance on alternative funding opportunities such as the signature research center proposal descried elsewhere in this report.

5. We need to increase collaborations with OHSU to provide more opportunities for clinical experiences for our students, particularly in competition with the new private school of pharmacy, and to develop avenues for more clinically relevant and NIH-appealing health outcomes research

6. Retention of Pharmacy Practice faculty with clinical skills will continue to be challenge as long as market forces continue to push pharmacists’ salaries that are significantly higher than current faculty salaries.  The recently approved equity adjustment for pharmacy faculty partially addresses this issue, but is also important to pursue faculty models that allow compensation from practice plans or as part of joint appointments.

7. Similarly, retention and promotion of PhD faculty will be a challenge without improved salary packages and without building a support network for collaborative research within disciplines.  Recent hires have been targeted to build areas of common research strength.

8. There is a need to grow our academic programs to address the continuing shortage of pharmacists while at the same time increasing efficiencies of instruction without adversely affecting our current high quality of instruction in academic, clinical, ethical and professional skills.  Initial discussions to explore the possibilities of developing branch campuses around the state, and using video and distance learning technology to provide instruction with existing faculty, have begun.  In addition to potentially increasing tuition revenue, such an initiative may also improve the ability of the college to recruit a more diverse student population and provide better pharmacy service to more remote regions of Oregon.

9. Identification of barriers to recruitment of students, faculty and staff from underrepresented populations will require a focused effort on the part of the entire faculty with the coordination of the diversity committee and input from experts at the University level.  The development of the colleges Diversity Action Plan is the first step in this process.

10. Global warming is beginning to wreak havoc with the building maintenance budget as air conditioners and cold rooms fail every time it reaches 106°C in Corvallis.

6. Proposed Priorities for 2006-2007, particularly in the areas of

▪ Student Engagement and Success

The curriculum will continue to be improved and refined as we review and implement recommendations from the assessment surveys that were part of the accreditation self-study. Both departments are conducting retreats this summer to review their curriculum with the intent to provide better articulation throughout three didactic years and with the experiential programs.

Through the capital campaign we propose to double the value of endowed scholarships over the next several years.

The college is scheduled for a ten year review of its graduate (MS and Ph.D.) programs by the graduate school during the coming academic year. Surveys of past graduates have been conducted and the policies and procedures manuals for the graduate program are undergoing extensive revision. We anticipate continued approval of our modestly sized, but outstanding graduate program.

▪ Increasing research/scholarship and outreach

The college will continue to focus its research on infectious disease drug discovery, translational research, use of genetically modified mice to model drug activity and disease state outcomes, health care economics studies, and creation of innovative practice models. Interdepartmental translational research projects in the areas of infectious diseases and clinical pharmacokinetics will be expanded as new faculty are hired. In particular we are excited about new funding that will come to OSU and the College of Pharmacy if the Oregon Drug Discovery & Translational Research Institute (ODDTRI) is approved by the Oregon Innovation Council (Oregon InC) for funding.

Our five year goal is to increase annual external funding to $3 million in external funding, $2.5 million of which will come from PHS/NIH funding. Success in meeting this goal is dependent on productivity of several newly hired faculty and our ability to recruit new faculty as discussed in greater detail throughout this report.

▪ Enhancing diversity and community

As indicated on page 15 and described in greater detail in Appendix C, the College has identified five planning priorities addressing diversity and community for the coming biennium.

1. Perform an assessment of retention of underrepresented and marginalized populations among the students, faculty, and staff within the college so that information can be obtained to establish future priorities focused on retention. This can be performed beginning the 2006- 2007 academic year. The measurable outcomes will be to have data by the end of the academic year.

2. Increase diversity competency efforts within the college by implementing a variety of required faculty and staff training sessions that address an array of diversity issues that will help them become culturally competent (e.g.,. Safe Space training). This can be done yearly at regularly scheduled faculty/staff meetings beginning 2006 – 2007 academic year. The measurable outcomes will be to track attendance.

3. Establish events or documents to promote and recognize the significant diversity that currently exists within the college. Promoting such events will establish a welcoming climate that recognizes the importance of diversity. One example of a current event is the Fall Luau during which the professional students organize a celebration of Luau traditions, such as the pig roast. An additional idea is to implement regularly scheduled pot-lucks for students, faculty and staff to celebrate the different heritages by sharing ethnic foods. This can be done regularly beginning 2006 – 2007 academic year. The measurable outcome will be to track attendance.

4. Identify barriers (i.e., monetary, marketing, or other) in the recruitment of students in the professional and graduate programs as well as faculty and staff from underrepresented populations. Assure student, faculty and staff success and retention by fostering a welcoming and inclusive, collaborative environment. Assistance will need to be in place to develop surveys to identify the barriers to recruitment and retention by each group. The measurable outcomes for the i) students, professional and graduate, will be to track progression through their respective programs; ii) faculty will be to track promotion and tenure status as well as turnover (hiring and resignation); and iii) staff will be to track promotion status as well as turnover (hiring and resignation).

5. Establish faculty liaisons to provide “permanent” links to the cultural centers such as OSU’s Black Cultural Center, Centro Cultural Cesar Chaves, Asian and Pacific Cultural Center, and Native American Longhouse as well as to the Women’s Center, Disabilities Services, and Pride Center. Set up a regular system for faculty liaisons to report on diversity issues at quarterly faculty meetings.

▪ Capital Campaign

Priorities for the capital campaign are unchanged from 2005-06. The college’s director of development resigned in July 2006. We look forward to rapid identification of a new college development director and renewed emphasis on visitations with alumni and other friends of the college.

Appendix A

Grants and Contracts

(Listed alphabetically by PI; College of Pharmacy faculty noted in bold font)

George Allen received an award from the Pharmacy Advisory Council for $5,000 to support research by P4 students completing my elective research clerkship in 2006-2007.

Jim Ayres has received a one-year research grant for Formulation of Novel Dosage Forms from Teva Pharmaceuticals USA in the amount of $80,000.

Zhengrong Cui received $29,968 from the Medical Research Foundation for a study titled “Development of novel anthrax DNA vaccine for non-invasive immunization.”

Zhengrong Cui has been awarded three grants:

1. CUI, PI, Oregon Sea Grant, Development of a vaccine against fish mycobacteriosis, $13,727

2. CUI, PI, OR-CAL Chemicals, Evaluation of the Anti-Tumor Activity of a proprietary compound, $7,075

3. CUI, PI, Elsa U. Pardee Foundation, A Double-Stranded RNA-Adjuvanted, Peptide-Based Vaccine for Cervical Cancer Immunotherapy, $59,183

Theresa Filtz received $20,000 from the Linus Pauling Institute as a pilot project grant titled “Effects of hawthorn (Crataegus) plant extracts on cultured cardiomyocytes and endothelial cells.”

The Pacific Mountain Affiliate Research Committee of the American Heart Association has approved a proposal submitted by Theresa Filtz entitled: Determination of active principles of Crataegus extract. The award will provide funding at the level of $66,000 per year over three years.

Patty Flatt was awarded $30,000 from the MRF Committee for her grant entitled "Molecular Evolution of the Paralomicin N-Glycosyltransferase For Use in Drug Design."

Patty Flatt was awarded $10,000 from the 2005-06 Spring General Research Fund for her proposal entitled: “Characterization of Pyralomicin Halogenases for Use in Drug Design.”

William Gerwick received a second installment of $160,616 for his five-year subaward from the Henry Ford Health System for a study titled, “Discovery and development of anticancer drugs from cyanobacteria.” In addition, he received $307,636 from National Institute of Neurological Disorders and Stroke for a four-year project titled “Neurotoxins from marine algae and cyanobacteria.”

Ann Hamer, Dean Haxby, Dan Hartung and Luke Middleton are Co-Investigators/collaborators on a grant awarded by the NIMH to the Department of Human Services, Office of Mental Health and Addiction Services entitled: Building the Foundation for Evidence-Based Practices in Oregon. Principal Investigator: David Pollack, MD Total Funding: $133,649

Jane Ishmael received $10,000 from the OSU General Research Fund for her proposal entitled: A Role for Myosin II in NMDA Receptor Dynamics.

Peter Hsu an undergraduate in Dr. Ishmael's laboratory was successful in receiving an $1,800 URISC award for his project entitled: "Characterization of a previously undescribed calmodulin binding site on the NMDA Receptor." The award will cover the cost Peter's salary in winter and spring terms and provide him with money for laboratory supplies.

Dale Kraemer received $35,231 as a subaward of an NIH grant at OHSU. The project is titled, “Statistical analysis of two compartment models to improve brain tumor therapy.”

Taifo Mahmud received the third installment ($233,024) of a four-year grant entitled “Biosynthesis Approach to Novel Aminocyclitols” from the National Institutes of Health.

Neil Henricksen, working with advisors Phil Proteau and Theresa Filtz, has received a Howard Hughes Medical Institute Summer Undergraduate Research Fellowship (coordinated at OSU by Kevin Ahern in the Biochemistry Department) for his research project, “The Identification and Characterization of the Cardioactive Principles in Hawthorn Extract”. Neil’s undergraduate institution is Walla Walla College.

Fred Stevens received $20,000 from the Linus Pauling Institute as principle investigator for a pilot project on enzymatic ascorbylation of oxidized lipids. The objective of the project is to demonstrate the presence of an enzyme that catalyzes the conjugation reaction of vitamin C with eletrophilic oxylipids in human hepatocytes.

Fred Stevens received $22,000 from a $240,297 USDA-CREES grant to study the effects of meadowfoam glucosinolates and their degradation products on phase I and phase II metabolic enzymes. Dr Russell Karow, Head of the Department of Crop and Soil Science, is the Principal Investigator on this grant and Fred Stevens’ role is co-Principal Investigator.

The National Institutes of Health/National Center for Research Resources has awarded the OSU campus Mass Spec Facility funding in the amount of $342,563 in response to the Shared Instrumentation Grant application, “Hybrid Triple Quadrupole Linear Ion Trap Mass Spectrometer.” Fred Stevens was the PI on the application.

Fred Stevens’ grant entitled "Oxidative Stress and Vitamin C Supplementation in Post-Surgery Patients" has been approved for funding by the MRF Committee in the amount of $30,000.

Fred Stevens received the first installment ($309,368) of his five-year grant, entitled “Ascorbylation of oxidized lipids and atherosclerosis” from the National Institutes of Health. Cristobal Miranda is the co-principal investigator on this grant.

John Turner, working in the lab of Mark Zabriskie, has received an Undergraduate Research, Innovation, Scholarship and Creativity award in the amount of $1,800 for his proposal titled “Identification of Antibiotics Produced by Microorganisms from the Indonesian Black Water Ecosystem.”

Xihou Yin was awarded $30.073.67 from the Medical Research Foundation of Oregon for research involving biosynthetic gene clusters.

A $29,800 award was made from Research Equipment Reserve Fund, which is administered by the OSU Research Office. The funds will go towards the purchase of a new High Performance Liquid Chromatograph (HPLC), Mark Zabriskie, PI.

Mark Zabriskie received the third installment of $239,962 from the NIH for a grant titled “Biosynthesis of Antitubercular Nonribosomal Peptides.”

Appendix B

Publications, Presentations, Awards, Travel, Service, and Other by Faculty

(Listed alphabetically by College of Pharmacy Faculty, noted in bold font)

Publications:

Bearden, DT, Holt T. State-wide impact of pharmacist-delivered adult influenza vaccinations. Am J Prev Med 2005;29:450-2.

Garey KW, Neuhauser MM, Bearden, DT, Cannon JP, Lewis RE, Gentry LO, Kontoyiannis DP. Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. Mycoses 2006;49(3):226-31.

Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden, DT. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin Infect Dis 2006;43:25-31.

Blanchard, D.L. and Zabriskie, T.M. Stereochemical control of capreomycidine biosynthesis, 46th Meeting of the American Society of Pharmacognosy, Corvallis, OR (July 2005)

Block John, Survey of Vitamins, Wiley’s Kirk-Othmer’s Encyclopedia of Chemical Technology, 5th ed., Article Online Posting Date: June 16, 2006.

Sowell J., Conway, H.M., Bruno R.S., Traber M.G., Frei B., Stevens, J.F., Ascorbylated 4-hydroxy-2-nonenal as a potential biomarker of oxidative stress response,

Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences, 2005 Nov 15;827(1):139-45. Epub 2005 Jul 14. PMID: 16023898 [PubMed - in process]

Cui, Zhengrong, DNA Vaccine, Advances in Genetics, 2005, 54, 258-289.

Cui, Zhengrong, Qiu, Fu, Sloat, Brian R., Lecithin-based cationic nanoparticles as a potential DNA delivery system, International Journal of Pharmaceutics, 313 (2006) 206-213.

Cui, Zhengrong, Dierling, Annie, Foldvari, Marianna, Non-Invasive Immunization on the Skin Using DNA Vaccine, Current Drug Delivery, 2006, 3, 29-35.

Dierling, Annie M., Cui, Zhengrong, Targeting primaquine into liver using chylomicron emulsions for potential vivax malaria therapy, International Journal of Pharmaceutics, 303 (2005) 143-152.

Fernandes, R.P.M., Phaosiri, C., Proteau, P.J., Mutation in the Flexible Loop of 1-Deoxy-D-xylulose 5-Phosphate Reductoisomerase Broadens Substrate Utilization, Archives of Biochemistry and Biophysics, 2005, 444, 159-164.

Fernandes, R.P.M.; Proteau, P.J. Kinetic Characterization of Synechocystis sp. PCC6803 1-Deoxy-D-xylulose 5-Phosphate Reductoisomerase Mutants, Biochimica et Biophysica Acta, 2006, 1764, 223-229.

Flatt, Patricia M., O'Connell, Susan J., McPhail, Kerry L., Zeller, Gloria, Willis, Christine L., Sherman, David H., Gerwick, William H, Characterization of the Initial Enzymatic Steps of Barbamide Biosynthesis, Journal of Natural Products (2006), 69(6), 938-944.

Grochowski, L.L. and Zabriskie, T.M., Characterization of BlsM, a Nucleotide Hydrolase Involved in Cytosine Production for the Biosynthesis of Blasticidin S., ChemBioChem 2006, 7, 957-964.

Metzger, D., Li M., Indra, A.K., Schuler, M. and Chambon, P., Conditional knockouts: Cre-Lox systems, Cell Biology : A laboratory Handbook.(Elsevier Sc.) (2006) Chapter 53, 501-509.

LePage K.T., Ishmael, J.E., Low, C.M., Traynelis, S.F. and Murray, T.F., Differential binding properties of [ 3H]dextrorphan and [ 3H]MK-801 in heterologously expressed NMDA receptors, Neuropharmacology, (2005) 49, 1-16.

Ito, MK. Comment: supratherapeutic response to ezetimibe administered with cyclosporine. Ann Pharmacother. 2005 Dec;39(12):2141. Epub 2005 Nov 15.

Gates R, Cookson T, Ito, M, Marcus D, Gifford A, Le TN, Nguyen CN. Therapeutic conversion from fosinopril to benazepril at a Veterans Affairs medical center. Am J Health Syst Pharm. 2006 Jun 1;63(11):1066-8.

Kristin R. Gilmer Knight, Dale F. Kraemer, and Edward A. Neuwelt. Ototoxicity in Children Receiving Platinum Chemotherapy: Underestimating a Commonly

Occurring Toxicity That May Influence Academic and Social Development. J Clin Oncol 2005;23:8588-8596.

Lieberman DA, Holub J, Eisen G, Kramer, D, Morris CD. Utilization of colonoscopy in the United States: results from a national consortium. Gastrointest Endosc 2005;62:875-83.

Le, Uyen M., Cui, Zhengrong, Long-circulating gadolinium-encapsulated liposomes for potential application in tumor neutron capture therapy, International Journal of Pharmaceutics, 312 (2006) 105-112.

Dickschat, JS; Bode, HB; Mahmud, T; Muller, R; Schulz, S., A novel type of geosmin biosynthesis in myxobacteria, Journal of Organic Chemistry, 2005. Published online.

Mahmud, T., Wenzel, S.C., Wan, E., Wen, K.W., Bode, H.B., Baitatzis, N., Muller, R., A novel biosynthetic pathway to isovaleryl-CoA in myxobacteria: The involvement of the mevalonate pathway, ChemBioChem, 2005, 6:322.

Mahadevan, B., Mata, J. E., Albershardt, D. J., Stevens, J. F., Pereira, C. B., Rodriguez-Proteau, R., Baird, W.M., The effects of red raspberry extract on PAH transport across Calu-3 cell monolayer, an in vitro cell model, International Journal Cancer Prevention, (2005) 2(2), 129-141.

Gafner, Stefan, Dietz, Birgit M., McPhail, Kerry L., Scott, Ian M., Glinski, Jan A., Russell, Fiona E., McCollom, Megan M., Budzinski, Jason W., Foster, Brian C., Bergeron, Chantal, Rhyu, Mee-Ra, Bolton, Judy L, Alkaloids from Eschscholzia californica and Their Capacity to Inhibit Binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A Receptors in Vitro, Journal of Natural Products (2006), 69(3), 432-435.

Torres-Mendoza, Daniel, Gonzalez, Jose, Ortega-Barria, Eduardo, Heller, Maria V., Capson, Todd L., McPhail, Kerry, Gerwick, William H., Cubilla-Rios, Luis, Weakly Antimalarial Flavonol Arabinofuranosides from Calycolpus warscewiczianus, Journal of Natural Products (2006), 69(5), 826-828.

Bai, L.; Li, L.; Xu, H.; Minagawa, K.; Yu, Y.; Zhang, Y.; Floss, H.G.; Zhou, X.; Mahmud, T.; Deng, Z. Functional Analysis of the Validamycin Biosynthetic Gene Cluster and Engineered Production of Validoxylamine A, Chemistry & Biology., 2006, 13, 387-397.

Yu, Y., Bai, L., Minagawa, K., Jian, X., Li, L., Li, J., Chen, S., Cao, E., Mahmud, T., Floss, H.G., Zhou, X., Deng, Z., A gene cluster encoding validamycin biosynthesis in Streptomyces hygroscopicus var. jinggangensis 5008, Applied and Environmental Microbiology, 2005, 71, 5066-5076.

Munar, MY, Singh, H. Acute Renal Failure. In: Helms R, Quan DJ (ed): Textbook of Therapeutics: Drug and Disease Management, 8th ed. Lippincott Williams & Wilkins, June 2006.

Rodriguez-Proteau, R., Mata, J. E., Miranda, C. L., Fan, Y., Brown, J. J., and Buhler, D. R., Plant polyphenols and multidrug resistance: Effects of dietary flavenoids on drug transporters in Caco-2 and MDCKII-MDR1 cell transport models, Xenobiotica 36 (1): 41 – 58, 2006.

Simmons, T. Luke, McPhail, Kerry L., Ortega-Barria, Eduardo, Mooberry, Susan L., Gerwick, William H., Belamide A, A new antimitotic tetrapeptide from a Panamanian marine cyanobacterium, Tetrahedron Letters, (2006), 47(20), 3387-3390.

Sloat, Brian R., Cui, Zhengrong, Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and nonanaesthetized mice, Journal of Pharmacy and Pharmacology, 2006, 58, 439-447.

Sloat, Brian R., Cui, Zhengrong, Strong Mucosal and Systemic Immunities Induced by Nasal Immunization with Anthrax Protective Antigen Protein Incorporated in Liposome-Protamine-DNA Particles, Pharmaceutical Research, Volume 23, No. 2, February 2006, 262-269.

Haltli, B., Tan, Y., Magarvey, N.A., Wagenaar, M., Yin, X., Greenstein, M., Hucul, J. and Zabriskie, T.M., Investigating β-Hydroxyenduracididine Formation in the Biosynthesis of the Mannopeptimcyins, Chemistry & Biology 2005, 12, 1163 – 1168.

Xu, J., Wan, E., Kim, C.J., Floss, H.G., Mahmud, T., Identification of Tailoring Genes Involved in the Formation of the Polyketide Backbone of Rifamycin B by Amycolatopsis mediterranei S699, Microbiology, 2005, 151, 2515-2528.

Wenzel, S.C., Meiser, P., Binz, T.M., Mahmud,T., Müller, R., Nonribosomal Peptide Biosynthesis: Point Mutations and Module Skipping Lead to Chemical Diversity, Angewandte Chemie International Edition, 2006, 45, 2296-2301

Woo, Y-H., Fernandes, R.P.M., Proteau, P.J., Evaluation of Fosmidomycin Analogs as Inhibitors of the Synechocystis sp. PCC6803 1-Deoxy-D-xylulose 5-Phosphate Reductoisomerase, Bioorganic and Medicinal Chemistry, 2006, 14, 2375-2385.

Xiong, Y., Wu, X., Mahmud, T., A homolog of Mycobacterium tuberculosis PapA5 protein, RifOrf20, is an acetyltransferase involved in the biosynthesis of antitubercular drug bifamycin B by Amycolatopsis mediterranei S699, ChemBioChem, 2005. 6:834.

Giri, S., Idle, J.R., Chen, C., Zabriskie, T.M., Krausz, K.W. and Gonzalez, F.J., A Metabolomic Approach to the Metabolism of the Areca Nut Alkaloids Arecoline and Aracaidine in the Mouse, Chemical Research in Toxicology, 2006, 818-827

 

Rachid, S., Krug, D., Kunze, B., Kochems, I., Scharfe, M., Zabriskie, T.M., Blöcker, H. and Müller, R., Molecular and biochemical studies of chondramide formation - highly cytotoxic natural products from Chondromyces crocatus Cm c5, Chemistry & Biology, 2006, 667-681.

Ritacco, F.V., Graziani, E.I., Summers, M.Y., Zabriskie, T.M., Yu, K., Bernan, V.S., Carter, G.T. and Greenstein, M., Production of Novel Rapamycin Analogs by Precursor-directed Biosynthesis, Applied and Environmental Microbiology, 2005, 71, 1971-1976.

Presentations:

Aebi, C. Chemotherapy induced nausea and vomiting. Oregon State Pharmacists Association Spring CE Meeting, Portland, OR, March 5, 2006 and Medford, OR, April 9, 2006.

Allen, GP, Bierman BC. Investigation of the mutant prevention concentration of linezolid for Enterococcus faecalis, Enterococcus faecium, and Staphylococcus aureus. American College of Clinical Pharmacy Spring Practice and Research Forum, Monterey, CA, April 2006.

Bearden, DT, Earle SB, McConnell DB, Belle DJ, Kohlhepp SJ. Pharmacokinetics of meropenem in extreme obesity. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, December 2005.

Bearden, DT presented a seminar, entitled ‘“A weighting game: Antibiotic dosing in obesity” at the Oregon Society of Health-System Pharmacists Annual Seminar in Sun River, Oregon, April 28-30, 2006.

Garey, KW, Reg, M, Pai, MP, Mingo DE, Suda KJ, Turpin RS, Bearden, DT. Time until initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, December 2005.

Conway, H.M., Gordillo, R., Kesinger, N.G., Sowell, J., Miranda, C.L., Stevens, J.F. (2006). Ascorbylation and Glutathionylation of Lipid Peroxidation Products as Potential Biomarkers of Oxidative Stress Response. 54th American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics, Seattle, Washington, May 28-June 1 (poster).

Fan, Y. and Rodriguez-Proteau, R. “Effects of ketoconazole on multidrug resistant-mediated transport in Caco-2 and MDCKII-MDR1 drug transport models” Toxicological Sciences, The Toxicologist, 80 (1-S), Abstract #1686. Society of Toxicology Annual Meeting, San Diego, CA, 2006.

Fei, X., Yin, X. and Zabriskie, T.M. Studies on three proteins in viomycin biosynthesis. 46th Meeting of the American Society of Pharmacognosy, Corvallis, OR (July 2005)

Flatt, P.M.; Wu, X.; Mahmud, T. Isolation and Characterization of the Pyralomicin Biosynthetic Gene Cluster. Volcano Conference in Bioorganic Chemistry, Feb. 24-26, 2006, Pack Forest Research Station, Eatonville, WA (Poster Presentation)

Ishmael, J. Regulation of NMDA receptor function by Myosin II Department of Physiology and Pharmacology, College of Veterinary Medicine at the University of Georgia in Athens, Georgia (invited speaker)

Ishmael, J; Bajaj,G.; Yang, J. and Amparan, D. Direct Interaction of a Myosin Light Chain with the Membrane-proximal Region of NMDA Receptor Subunits. Annual Meeting of the Society for Neuroscience, November 2005, Washington D.C. (Poster)

Cheung RJ, Ito, MK, Henry RR. Is the cholesterol lowering response to a statin and a cholesterol absorption inhibitor inversely related? A prospective, randomized, cross-over design study. Poster presentation at the 2005 Annual Meeting of the American College of Clinical Pharmacy. San Francisco, CA. October 26, 2005

Ito, MK. Practical Aspects of Lipid Management. Oral presentation at the 2005 Annual Meeting of the American College of Clinical Pharmacy. San Francisco, CA. October 22, 2005

Ito, MK. What if Cholesterol Lowering is Just Part of the Story? Oral presentation at the 2005 Annual Meeting of the American College of Clinical Pharmacy. San Francisco, CA. October 25, 2005.

Ito MK. New Data Sets for Statins, Nonstatins, and Diabetes for LDL-C Lowering. Pharm-Med Updates meeting, Los Angeles, CA - May 11, 2006

Ito MK, Aldridge VE, Howard JJ, Gupta EK, Johns ST, Wong JK. “Effects of an Encapsulated Formulation of Pravastatin on Plasminogen Activator Inhibitor-1 in Patients with Human Immunodeficiency Virus Infection.” 7th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology, Denver, CO - April 29, 2006.

Kesinger, N.G., Morré, J., Machado, S., Stevens, J.F. (2006). LC-MS/MS Analysis of Glucosinolates and their Enzymatic Degradation Products in Meadowfoam Seed Meal. 54th American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics, Seattle, Washington, May 28-June 1 (poster).

Linares R and Zweber A, Home Testing Kits, Oregon State Pharmacists Association Spring CE Meeting, Portland, OR, March 5, 2006 and Medford, OR, April 9, 2006

Mahmud, T., Biosynthesis of Microbial-Derived Aminocyclitol Family of Natural Products. 231st American Chemical Society (ACS) National Meeting, March 26-March 30, 2006, Atlanta, Georgia. (Invited Oral Presentation at the Ernest Guenther Award Symposium).

Minagawa, K.; Zhang, Y.; Ito, T.; Bai, L.; Deng, Z.; Mahmud, T. Functional Analysis of the Cyclitol Kinase ValC Involved in Validamycin A Biosynthesis. Volcano Conference in Bioorganic Chemistry, Feb. 24-26, 2006, Pack Forest Research Station, Eatonville, WA (Poster Presentation)

Miranda, C.L., Chung, W.G., Li, H.J., Stevens, J.F., Maier, C.S. (2006). A Proteomic Approach for Evaluating the Effects of Proanthocyanidins on Rotenone-Induced Toxicity in SH-SY5Y Neuroblastoma Cells. 54th American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics, Seattle, Washington, May 28-June 1 (poster).

Moretz, D. "Pharmacy Perspectives on Pain Management" Oral presentation at the 2005 Oregon Nurses Association Meeting. Salem, OR October 26, 2005

Moretz, D. "Preceptor Workshop - The Art of Evaluating Students" Moderator and speaker. Portland, OR November 1, 2005

Moretz, D. presented "Perspectives on Pain Management" on February 19, for the Lane County Pharmaceutical Association, on February 22 to the Oregon Nursing Association, and on March 15 at the SAIF Pain Management Conference 2006.

Moretz, D. presented "Precepting and Evaluating Clerkship Students" on February 25, at the OSHP Winter Festival

Moretz, D. presented “Pharmacy Perspectives on Pain Management" date and site?

"Novel Tobramycin Dosing in Hemodialysis to Minimize Toxicity" Osama Mohamed, PhD, Myrna Y. Munar, PharmD, Sandra B. Earle, PharmD, James W. Ayres, PhD, William M. Bennett, MD, Suzanne Watnick, MD, Ihab Wahba, MD. Poster presentation at the American Society of Nephrology Annual Meeting, November 11, 2005, Philadelphia, PA

Nauman, D: “Cross-Practice Comparison of Preceptor Evaluations of Student Professionalism and Ethical Conduct During Early Experiential Rotations” abstract accepted as a poster presentation at AACP 2006 Annual Meeting in San Diego, CA in July 2006.

Nauman, D: Developed an Immunization Delivery Certification Program for the OSU College of Pharmacy. Ms. Nauman presented a program overview to the members of the Oregon Board of Pharmacy at their meeting in February 2006.

Sheeba,V.; Flatt, P.M.; Mahmud, T. Overexpression and Enzymatic Study of Nucleotidylyltransferases from the Validamycin and Acarbose Gene Clusters. Volcano Conference in Bioorganic Chemistry, Feb. 24-26, 2006, Pack Forest Research Station, Eatonville, WA (Poster Presentation)

Han, B., Stevens, J.F., Maier, C.S. (2006). Carbonylated Proteins Probed by a Hydrazide-Functionalized Isotope-Coded Affinity Tag (HICAT). 54th American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics, Seattle, Washington, May 28-June 1 (poster).

Wan, E.; Mahmud, T. Mutagenetic Approaches to Novel Myxalamids in Stigmatella aurantiaca. Volcano Conference in Bioorganic Chemistry, Feb. 24-26, 2006, Pack Forest Research Station, Eatonville, WA (Poster Presentation)

Wu, X.; Flatt, P.M.; Mahmud, T. Biosynthetic Studies on the Antitumor Agent Cetoniacytone A. Volcano Conference in Bioorganic Chemistry, Feb. 24-26, 2006, Pack Forest Research Station, Eatonville, WA (Oral Presentation)

Xiong, Y.; Mahmud, T. Genetic and Synthetic Approaches to New Antitubercular Drugs. Volcano Conference in Bioorganic Chemistry, Feb. 24-26, 2006, Pack Forest Research Station, Eatonville, WA (Poster Presentation)

Xiong, Y.; Mahmud, T. Genetic and Combinatorial Synthetic Aproaches To Novel Rifamycin Analogs. Gordon Research Conference on New Antibacterial Drug Discovery and Development, March 5-March 10, 2006, Ventura, California. (Poster Presentation)

Yao, Q. and Proteau, P.J. Cloning the Diterpene Gene Cluster for the Fungal Antibiotic Pleuromutilin, Volcano Conference in Bioorganic Chemistry, Pack Forest, WA, February 24-26, 2006, (Poster presentation)

Yin, X. Tan, T., Zhang, L. and Zabriskie, T.M. Cloning, sequence and initial characterization of the enduracidin biosynthetic gene cluster. Gordon Research Conference on New Antibiotic Development, Ventura, CA (March 2006)

Brooks AM and Zweber A, Increasing Cultural Competency and Health Literacy, American Pharmacists Association Annual Meeting and Exposition, San Francisco, CA, March 18, 2006

Yin, X. and Zabriskie, T.M. Molecular genetic studies on the viomycin biosynthesis genes. 46th Meeting of the American Society of Pharmacognosy, Corvallis, OR (July 2005)

Zabriskie, T.M., Portland State University, Department of Chemistry, Portland, OR (February) Precursor amino acid formation and post-assembly tailoring associated with nonribosomal peptide antibiotic biosynthesis in Streptomyces spp.

Zweber A and Watt M, Oregon Board of Pharmacy Technician Update, Oregon State Pharmacists Association Spring CE Meeting, Portland, OR, March 5, 2006 and Medford, OR, April 9, 2006

Zweber A and Dowling B, Assessing English Language Proficiency during the Interview Process, American Association of Colleges of Pharmacy Interim Meeting, San Antonio, TX, March 1, 2006

Zweber, A, OTCs on the Horizon, APhA’s Self-Care Institute Annual Meeting, Baltimore, MD, June 24, 2006.

Campbell C and Zweber A, Panel on Pharmacy Refusals, OSU Women's Center, Corvallis, OR, May 4, 2006.

Awards/Certifications:

Ann Hamer is now a Board Certified in Psychopharmacotherapy by the Board of Pharmaceutical Specialties.

Moretz D Received OSHP President's Award for sustained contribution and leadership to OSHP.

Moretz D. has received BCPS recertification for 2006-2013

Travel and Professional Service:

John Block attended the following meetings of the National Association of Boards of Pharmacy’s Foreign Pharmacy Graduate Equivalency Examination Committee

January 9 - Chicago

Examination Blueprint Revision (1-day meeting)

March 23 – 26  San Diego

Review questions for the June examination

April 27 – 30  Chicago

Medicinal Chemist Facilitator at an item writing session where faculty write questions for the examination.

Mark Christensen was featured in an article entitled, “Soap, water: Magic potion to stop poison plant itch” in the March 16 edition of OSU This Week. Dr. Christensen was interviewed for his insights in treating and preventing poison oak and poison ivy.

Gary DeLander presented as part of a panel entitled Paws, People and Pills: Veterinary, Public Health and Pharmacy. The panel focused on non-academic considerations in admissions to professional schools and was part of the annual meeting of the National Association of Advisors for Health Professions meeting in Portland on June 28, 2006.

Gary DeLander joined Ann Zweber and Wayne Kradjan in attending the interim AACP meeting. The meeting was focused largely on issues related to diversity.

Gary DeLander, Ann Zweber, Diane Nauman, and Matt Ito attended a national AACP retreat to examine opportunities and alternatives to enhance experiential education.

Theresa Filtz has been appointed Secretary/Treasurer-Elect for the Molecular Pharmacology division of ASPET.

Graduate students in the College met to present their research at the 2006 College of Pharmacy Research Retreat, April 7-8, 2006, Salishan Spa and Golf Resort, Gleneden Beach, Oregon, as previously reported in the research retreat program.

Jane Ishmael was an invited speaker at the March meeting of the local Migraine and Headache Support Group in Corvallis where she discussed, "Migraine versus Chronic Daily Headache."

The Board of Directors of the American Society of Pharmacognosy Foundation identified Taifo Mahmud as a recipient of this year’s Matt Suffness Award, in recognition of his research in the area of natural products. The award was presented at the 47th Annual Meeting of the ASP annual banquet on August 9, 2006, in Washington D.C.

Taifo Mahmud was initiated as a member of the Honor Society of Phi Kappa Phi, Oregon State University Chapter on May 4, 2006.

Taifo Mahmud attended the Gordon Research Conference on New Antibacterial Drug Discovery and Development, March 5-March 10, 2006, Ventura, California.

Taifo Mahmud attended the 231st American Chemical Society (ACS) National Meeting, March 26-March 30, 2006, Atlanta, Georgia.

Kerry McPhail attended the Gordon Research Conference on Marine Natural Products February 26-March 3, 2006.

Phil Proteau, Taifo Mahmud, Patty Flatt and several graduate students in Medicinal Chemistry and Natural Products attended the annual Volcano Conference at Pack Forest, Washington.

Rosita Proteau and Ying Fan attended the Society of Toxicology (SOT) 2006 Annual meeting in San Diego. Dr. R. Proteau has served on SOT’s Education Committee for the past three years and is now the Chair of the Education Committee. The Education Committee is responsible for numerous activities at the annual meeting which include the K-12 Paracelsus goes to School Workshop, Minority Undergraduate Program, Novartis Graduate Fellowship Interviews, Pfizer Undergraduate Travel Awards, and the Distance Education Symposium. Dr. Proteau also served as the “Final Manuscript Judge” for the Carl C. Smith Student Awards from SOT’s Mechanisms Specialty Section as well as serving as SOT’s Regional Chapter President of the Pacific Northwest Association of Toxicologists.

Fred Stevens presented a seminar, entitled ‘Ascorbylation of natural products and oxidized lipids’, at the University of Illinois, Chicago (UIC), on April 28, 2006. This seminar was hosted by the Department of Medicinal Chemistry and Pharmacognosy at UIC.

Fred Stevens presented the 2006 John Bauers lecture, entitled ‘Xanthohumol and other beer flavonoids: To your good health!?’ in Portland on May 7, 2006. This lecture was hosted by the Society of Physicians for Wine and Health.

Patents Awarded:

United States: Number 6,964,782, Stable hydrogen peroxide compositions, products and methods of use. Granted November 15, 2005.

Inventors:

Robert Lee Smith, Steven Dale Smith, Wendy S. Langley, Vernon W. Smith, John Mark Christensen.

Appendix C

Diversity Action Plan

College of Pharmacy

Sent as separate attachment

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download